Lycia Therapeutics, a clinical-stage biopharma focused on autoimmune and inflammatory diseases, has filed for an IPO to raise capital. Its lead drug candidate, LCA-0061, is showing promising results in Phase 1 trials by significantly reducing IgE levels, targeting the expanding food allergy market. The IPO proceeds will support the advancement of multiple clinical programs into more costly development stages. Given positive early data and strong biopharma IPO performance in 2026, the offering is expected to attract strong institutional interest if priced fairly.
Lycia Therapeutics' IPO filing is the subject here, with Pluang data providing market context. Of 128 priced Health-sector US stocks tradable on Pluang, 51 rose and 77 fell today. Notable movers include CGC at USD 0.84 (-4.20%), AHCO at USD 6.10 (+3.74%) with 75% sell order activity, and IOVA at USD 13.32 (+3.18%) with 100% buy order activity. This data is as of Oct 09, 2026 05:21 WIB.
Tech analyst James Altucher highlights a publicly available but overlooked government filing that outlines Elon Musk's detailed plan for artificial intelligence. The filing, buried beneath the attention-grabbing SpaceX IPO news, reveals concrete step...
The Canine Project announced the launch of FURVIVE, an all-in-one restorative shampoo, conditioner, and body wash for dogs, set to release on October 15, 2026. Created by skincare experts, FURVIVE features Brazilian Copaiba and other premium skincare...
EnergyLIB is entering a new growth phase following a proposed strategic investment by Nasdaq-listed Cheche Group in its residential solar-plus-storage business, Long Way Fortune. This investment supports Cheche Group's expansion into the global resid...
Parex Resources announced its Q3 2026 average production reached 83,259 barrels of oil equivalent per day, driven by exploration success and a partnership with Ecopetrol. The company reaffirmed its H2 2026 production guidance of 82,000 to 91,000 boe/...
The Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased The Ensign Group securities between February 2022 and June 2026. The lawsuit alleges that Ensign systematically neglected elderly residents in its care facilitie...
